261 related articles for article (PubMed ID: 35892315)
1. Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Guijosa A; Freyria A; Espinosa-Fernandez JR; Estrada-Mena FJ; Armenta-Quiroga AS; Ortega-Treviño MF; Catalán R; Antonio-Aguirre B; Villarreal-Garza C; Perez-Ortiz AC
Clin Transl Sci; 2022 Oct; 15(10):2403-2436. PubMed ID: 35892315
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Frederiks CN; Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2015 Dec; 41(10):935-50. PubMed ID: 26585358
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103.
Shen F; Jiang G; Philips S; Gardner L; Xue G; Cantor E; Ly RC; Osei W; Wu X; Dang C; Northfelt D; Skaar T; Miller KD; Sledge GW; Schneider BP
Clin Cancer Res; 2023 Jul; 29(13):2494-2500. PubMed ID: 37126018
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211
[TBL] [Abstract][Full Text] [Related]
5. Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
Abe Y; Taira N; Kashiwabara K; Tsurutani J; Kitada M; Takahashi M; Kato H; Kikawa Y; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Takashima T; Aihara T; Mukai H; Hara F; Shien T; Doihara H; Toyooka S
Acta Med Okayama; 2022 Dec; 76(6):661-671. PubMed ID: 36549768
[TBL] [Abstract][Full Text] [Related]
6.
McEvoy L; Cliff J; Carr DF; Jorgensen A; Lord R; Pirmohamed M
Front Pharmacol; 2023; 14():1178421. PubMed ID: 37469869
[No Abstract] [Full Text] [Related]
7. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
Leandro-García LJ; Inglada-Pérez L; Pita G; Hjerpe E; Leskelä S; Jara C; Mielgo X; González-Neira A; Robledo M; Avall-Lundqvist E; Gréen H; Rodríguez-Antona C
J Med Genet; 2013 Sep; 50(9):599-605. PubMed ID: 23776197
[TBL] [Abstract][Full Text] [Related]
8. The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer.
Hjorth CF; Damkier P; Stage TB; Feddersen S; Hamilton-Dutoit S; Ejlertsen B; Lash TL; Bøggild H; Sørensen HT; Cronin-Fenton D
Cancer Chemother Pharmacol; 2023 Feb; 91(2):157-165. PubMed ID: 36598552
[TBL] [Abstract][Full Text] [Related]
9. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Hertz DL; Roy S; Jack J; Motsinger-Reif AA; Drobish A; Clark LS; Carey LA; Dees EC; McLeod HL
Breast Cancer Res Treat; 2014 May; 145(1):245-54. PubMed ID: 24706167
[TBL] [Abstract][Full Text] [Related]
10. A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol.
Sharma A; Johnson KB; Bie B; Rhoades EE; Sen A; Kida Y; Hockings J; Gatta A; Davenport J; Arcangelini C; Ritzu J; DeVecchio J; Hughen R; Wei M; Thomas Budd G; Lynn Henry N; Eng C; Foss J; Rotroff DM
Technol Cancer Res Treat; 2022; 21():15330338221127169. PubMed ID: 36172750
[No Abstract] [Full Text] [Related]
11. Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
Tamburin S; Park SB; Alberti P; Demichelis C; Schenone A; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S40-S51. PubMed ID: 31647157
[TBL] [Abstract][Full Text] [Related]
12. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Rizzo R; Spaggiari F; Indelli M; Lelli G; Baricordi OR; Rimessi P; Ferlini A
Breast Cancer Res Treat; 2010 Nov; 124(2):593-8. PubMed ID: 20632082
[TBL] [Abstract][Full Text] [Related]
13. Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.
Pabst L; Velten M; Fischbach C; Kalish M; Pflumio C; Pivot X; Petit T
Breast J; 2020 Dec; 26(12):2376-2382. PubMed ID: 33307596
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
Angelini S; Botticelli A; Onesti CE; Giusti R; Sini V; Durante V; Strigari L; Gentile G; Cerbelli B; Pellegrini P; Sgroi V; Occhipinti M; DI Pietro FR; Rossi A; Simmaco M; Mazzuca F; Marchetti P
Anticancer Res; 2017 May; 37(5):2633-2639. PubMed ID: 28476838
[TBL] [Abstract][Full Text] [Related]
15. Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.
Lam SW; Frederiks CN; van der Straaten T; Honkoop AH; Guchelaar HJ; Boven E
Br J Cancer; 2016 Nov; 115(11):1335-1342. PubMed ID: 27736846
[TBL] [Abstract][Full Text] [Related]
16. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Abraham JE; Guo Q; Dorling L; Tyrer J; Ingle S; Hardy R; Vallier AL; Hiller L; Burns R; Jones L; Bowden SJ; Dunn JA; Poole CJ; Caldas C; Pharoah PP; Earl HM
Clin Cancer Res; 2014 May; 20(9):2466-75. PubMed ID: 24599932
[TBL] [Abstract][Full Text] [Related]
17. SNPs and taxane toxicity in breast cancer patients.
Bosó V; Herrero MJ; Santaballa A; Palomar L; Megias JE; de la Cueva H; Rojas L; Marqués MR; Poveda JL; Montalar J; Aliño SF
Pharmacogenomics; 2014; 15(15):1845-58. PubMed ID: 25495407
[TBL] [Abstract][Full Text] [Related]
18. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer.
Song SJ; Min J; Suh SY; Jung SH; Hahn HJ; Im SA; Lee JY
Support Care Cancer; 2017 Jul; 25(7):2241-2248. PubMed ID: 28204996
[TBL] [Abstract][Full Text] [Related]
19. A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.
Ciruelos E; Apellániz-Ruiz M; Cantos B; Martinez-Jáñez N; Bueno-Muiño C; Echarri MJ; Enrech S; Guerra JA; Manso L; Pascual T; Dominguez C; Gonzalo JF; Sanz JL; Rodriguez-Antona C; Sepúlveda JM
Oncologist; 2019 Nov; 24(11):e1024-e1033. PubMed ID: 31023863
[TBL] [Abstract][Full Text] [Related]
20. Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans.
Schneider BP; Lai D; Shen F; Jiang G; Radovich M; Li L; Gardner L; Miller KD; O'Neill A; Sparano JA; Xue G; Foroud T; Sledge GW
Oncotarget; 2016 Dec; 7(50):82244-82253. PubMed ID: 27732968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
